The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Empagliflozin after Acute Myocardial Infarction
Open accessAbstract
BACKGROUND: Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety and efficacy of empagliflozin in patients who have had acute myocardial infarction are unknown. METHODS: In this event-driven, double-blind, randomized, placebo-controlled trial, we assigned, in a 1:1 ratio, patients who had been hospitalized for acute myocardial infarction and were at risk for heart failure to receive empagliflozin at a dose of 10 mg daily or placebo in addition to standard care within 14 days after admission. The primary end point was a composite of hospitalization for heart failure or death from any cause as assessed in a time-to-first-event analysis. RESULTS: A total of 3260 patients were assigned to receive empagliflozin and 3262 to receive placebo. During a median follow-up of 17.9 months, a first hospitalization for heart failure or death from any cause occurred in 267 patients (8.2%) in the empagliflozin group and in 298 patients (9.1%) in the placebo group, with incidence rates of 5.9 and 6.6 events, respectively, per 100 patient-years (hazard ratio, 0.90; 95% confidence interval [CI], 0.76 to 1.06; P = 0.21). With respect to the individual components of the primary end point, a first hospitalization for heart failure occurred in 118 patients (3.6%) in the empagliflozin group and in 153 patients (4.7%) in the placebo group (hazard ratio, 0.77; 95% CI, 0.60 to 0.98), and death from any cause occurred in 169 (5.2%) and 178 (5.5%), respectively (hazard ratio, 0.96; 95% CI, 0.78 to 1.19). Adverse events were consistent with the known safety profile of empagliflozin and were similar in the two trial groups. CONCLUSIONS: Among patients at increased risk for heart failure after acute myocardial infarction, treatment with empagliflozin did not lead to a significantly lower risk of a first hospitalization for heart failure or death from any cause than placebo. (Funded by Boehringer Ingelheim and Eli Lilly; EMPACT-MI ClinicalTrials.gov number, NCT04509674.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Frantz, S., Hundertmark, M. J., Schulz-Menger, J., Bengel, F. M., & Bauersachs, J. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac223 · Cited by 606
Self-citationSteg, P. G., Dabbous, O. H., Feldman, L. J., Cohen-Solal, A., Aumont, M.-C., López-Sendón, J., Budaj, A., Goldberg, R. J., Klein, W., & Anderson, F. A. (2004) · Circulation · doi:10.1161/01.cir.0000109691.16944.da · Cited by 550
Self-citationAngiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction
Pfeffer, M. A., Claggett, B., Lewis, E. F., Granger, C. B., Køber, L., Maggioni, A. P., Mann, D. L., McMurray, J. J. V., Rouleau, J.-L., Solomon, S. D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104508 · Cited by 307
Self-citationDapagliflozin in Myocardial Infarction without Diabetes or Heart Failure
James, S., Erlinge, D., Storey, R. F., McGuire, D. K., de Belder, M., Eriksson, N., Andersen, K., Austin, D., Arefalk, G., Carrick, D., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2300286 · Cited by 305
Empagliflozin in acute myocardial infarction: the EMMY trial
von Lewinski, D., Kolesnik, E., Tripolt, N. J., Pferschy, P. N., Benedikt, M., Wallner, M., Alber, H., Berger, R., Lichtenauer, M., Saely, C. H., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac494 · Cited by 303
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Usman, M., Siddiqi, T. J., Anker, S. D., Bakris, G. L., Bhatt, D. L., Filippatos, G. S., Fonarow, G. C., Greene, S. J., Januzzi, J. L., Khan, M. S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.034 · Cited by 184
Self-citationZaman, S. J., & Kovoor, P. (2014) · Circulation · doi:10.1161/circulationaha.113.007497 · Cited by 131
Change in Left Ventricular Ejection Fraction Following First Myocardial Infarction and Outcome
Chew, D. S., Heikki, H., Schmidt, G. P., Kavanagh, K. M., Dommasch, M., Thomsen, P. E. B., Sinnecker, D., Raatikainen, P. M. J., & Exner, D. V. (2018) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2017.12.015 · Cited by 117
Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic
Hall, M. E., Vaduganathan, M., Khan, M. S., Papadimitriou, L., LONG, R. C., Hernandez, G. A., Moore, C. K., Lennep, B., McMullan, M. R., & Butler, J. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.05.005 · Cited by 117
Self-citationDocherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Böhm, M., de Boer, R. A., DeMets, D. L., Desai, A. S., Drozdz, J., Howlett, J., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047480 · Cited by 95
Self-citationAcute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome
Harrington, J., Jones, W. S., Udell, J. A., Hannan, K. L., Bhatt, D. L., Anker, S. D., Petrie, M. C., Vedin, O., Butler, J., & Hernandez, A. F. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.02.008 · Cited by 93
Self-citationEmpagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial
Harrington, J., Udell, J. A., Jones, W. S., Anker, S. D., Bhatt, D. L., Petrie, M. C., Vedin, O., Sumin, M., Zwiener, I., Hernandez, A. F., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.05.010 · Cited by 81
Self-citationSjöblom, J., Muhrbeck, J., Witt, N., Alam, M., & Frykman, V. (2014) · Circulation · doi:10.1161/circulationaha.114.009924 · Cited by 75
Influence of Age on the Diagnosis of Myocardial Infarction
Lowry, M. T. H., Doudesis, D., Wereski, R., Kimenai, D. M., Tuck, C. E., Ferry, A. V., Bularga, A., Taggart, C., Lee, K. K., Chapman, A. R., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059994 · Cited by 55
Desta, L., Jernberg, T., Spaak, J., Hofman‐Bang, C., & Persson, H. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.086 · Cited by 47
James, S. K., Erlinge, D., Storey, R. F., McGuire, D. K., de Belder, M., Björkgren, I., Johansson, P. A., Langkilde, A. M., Ridderstråle, W., Rizi, E. P., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.08.008 · Cited by 40
Butler, J., Packer, M., Greene, S. J., Fiuzat, M., Anker, S. D., Anstrom, K. J., Carson, P. E., Cooper, L. B., Fonarow, G. C., Hernandez, A. F., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042155 · Cited by 30
Self-citationThe High-Risk Myocardial Infarction Database Initiative
Dickstein, K., Bebchuk, J. D., & Wittes, J. T. (2012) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2011.10.001 · Cited by 29
Baseline Characteristics of Patients Enrolled in the EMPACT-MI Trial
Harrington, J., Udell, J. A., Jones, W. S., Anker, S. D., Bhatt, D. L., Petrie, M. C., Andersen, K. R., Sumin, M., Zwiener, I., Hernandez, A. F., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2990 · Cited by 21
Self-citationButler, J., Anker, S. D., Filippatos, G., Usman, M. S., Ferreira, J. P., Zannad, F., & Packer, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab704 · Cited by 18
Self-citation
Cited by
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · JACC · doi:10.1016/j.jacc.2024.11.009 · Cited by 552
Obesity accelerates cardiovascular ageing
Ruperez, C., Madeo, F., de Cabo, R., Kroemer, G., & Abdellatif, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf216 · Cited by 73
Kani, R., Miyamoto, Y., Saito, T., Watanabe, A., Matsubara, K., Ejiri, K., Iwagami, M., Slipczuk, L., Hosseini, K., Fujisaki, T., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133079 · Cited by 10
Hierarchical endpoints and win statistics for geromedicine trials
Abdellatif, M., Kim, Y., & Kroemer, G. (2026) · Nature Aging · doi:10.1038/s43587-026-01158-3
Metadata
- Authors
- Butler, J., Jones, W. S., Udell, J. A., Anker, S. D., Petrie, M. C., Harrington, J., Mattheus, M., Zwiener, I., Amir, O., Bahit, M. C., Bauersachs, J., Bayes-Genis, A., Chen, Y., Chopra, V. K., Figtree, G., Ge, J., Goodman, S. G., Gotcheva, N., Goto, S., Gasior, T., Jamal, W., Januzzi, J. L., Jeong, M. H., Lopatin, Y., Lopes, R. D., Merkely, B., Parikh, P. B., Parkhomenko, A., Ponikowski, P., Rossello, X., Schou, M., Simic, D., Steg, P. G., Szachniewicz, J., van der Meer, P., Vinereanu, D., Zieroth, S., Brueckmann, M., Sumin, M., Bhatt, D. L., & Hernandez, A. F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-04-25
- Volume
- 390
- Issue
- 16
- Pages
- 1455-1466
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4394009954
- Cited by
- 301
- References
- 25
- FWCI
- 81.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.